Compare RWT & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | VIR |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.0M | 773.5M |
| IPO Year | 1995 | 2019 |
| Metric | RWT | VIR |
|---|---|---|
| Price | $5.62 | $6.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $7.00 | ★ $25.73 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 12.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,897,000.00 | $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.22 | $48.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.68 | $4.16 |
| 52 Week High | $7.19 | $14.45 |
| Indicator | RWT | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 61.51 |
| Support Level | $5.45 | $6.49 |
| Resistance Level | $5.70 | $6.89 |
| Average True Range (ATR) | 0.13 | 0.47 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 86.72 | 83.17 |
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.